Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
microbiome therapeutic
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:composition |
defined bacterial consortium
|
| gptkbp:developedBy |
gptkb:Vedanta_Biosciences
|
| gptkbp:form |
oral
|
| https://www.w3.org/2000/01/rdf-schema#label |
VE303
|
| gptkbp:indication |
gptkb:Clostridioides_difficile_infection
|
| gptkbp:mechanismOfAction |
restores gut microbiome
|
| gptkbp:regulates |
not yet approved
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sponsor |
gptkb:Vedanta_Biosciences
|
| gptkbp:status |
investigational
|
| gptkbp:targetAudience |
patients with recurrent C. difficile infection
|
| gptkbp:therapeuticArea |
infectious diseases
|
| gptkbp:bfsParent |
gptkb:Vedanta_Biosciences
|
| gptkbp:bfsLayer |
5
|